Диссертация (1140781), страница 17
Текст из файла (страница 17)
83-89.37. Chan Y. H., Yeh Y. H., See L. C., Wang C. L., Chang S. H., Lee H. F., Wu L. S., TuH. T., Kuo C. T. Acute Kidney Injury in Asians With Atrial Fibrillation Treated WithDabigatran or Warfarin // J Am Coll Cardiol. ‒ 2016. ‒ T. 68, № 21. ‒ C. 2272-2283.38. Chatrou M. L., Winckers K., Hackeng T. M., Reutelingsperger C. P., Schurgers L. J.Vascular calcification: the price to pay for anticoagulation therapy with vitamin Kantagonists // Blood Rev. ‒ 2012.
‒ T. 26, № 4. ‒ C. 155-66.39. Chugh S. S., Havmoeller R., Narayanan K., Singh D., Rienstra M., Benjamin E. J.,Gillum R. F., Kim Y. H., McAnulty J. H., Zheng Z. J., Forouzanfar M. H., Naghavi M.,Mensah G. A., Ezzati M., Murray C. J. Worldwide epidemiology of atrial fibrillation: aGlobal Burden of Disease 2010 Study // Circulation. ‒ 2014. ‒ T. 129, № 8. ‒ C. 837-47.40. Colilla S., Crow A., Petkun W., Singer D. E., Simon T., Liu X. Estimates of currentand future incidence and prevalence of atrial fibrillation in the U.S. adult population //Am J Cardiol. ‒ 2013. ‒ T.
112, № 8. ‒ C. 1142-7.41. Collins A. J., Kasiske B., Herzog C., Chavers B., Foley R., Gilbertson D., Grimm R.,Liu J., Louis T., Manning W., Matas A., McBean M., Murray A., St Peter W., Xue J., FanQ., Guo H., Li S., Roberts T., Snyder J., Solid C., Wang C., Weinhandl E., Arko C., Chen114S. C., Dalleska F., Daniels F., Dunning S., Ebben J., Frazier E., Johnson R., Sheets D.,Forrest B., Berrini D., Constantini E., Everson S., Frederick P., Eggers P., Agodoa L.,System U.
S. R. D. Excerpts from the United States Renal Data System 2004 annual datareport: atlas of end-stage renal disease in the United States // Am J Kidney Dis. ‒ 2005. ‒T. 45, № 1 Suppl 1. ‒ C. A5-7, S1-280.42. Connolly S., Pogue J., Hart R., Pfeffer M., Hohnloser S., Chrolavicius S., Yusuf S.,Investigators A. W. G. o.
t. A. Clopidogrel plus aspirin versus oral anticoagulation foratrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for preventionof Vascular Events (ACTIVE W): a randomised controlled trial // Lancet. ‒ 2006. ‒ T.367, № 9526. ‒ C. 1903-12.43. Connolly S. J., Ezekowitz M. D., Yusuf S., Eikelboom J., Oldgren J., Parekh A.,Pogue J., Reilly P. A., Themeles E., Varrone J., Wang S., Alings M., Xavier D., Zhu J.,Diaz R., Lewis B.
S., Darius H., Diener H. C., Joyner C. D., Wallentin L., InvestigatorsR.-L. S. C. a. Dabigatran versus warfarin in patients with atrial fibrillation // N Engl JMed. ‒ 2009. ‒ T. 361, № 12. ‒ C. 1139-51.44. Connolly S. J., Eikelboom J., Joyner C., Diener H. C., Hart R., Golitsyn S., Flaker G.,Avezum A., Hohnloser S. H., Diaz R., Talajic M., Zhu J., Pais P., Budaj A., ParkhomenkoA., Jansky P., Commerford P., Tan R. S., Sim K.
H., Lewis B. S., Van Mieghem W., LipG. Y., Kim J. H., Lanas-Zanetti F., Gonzalez-Hermosillo A., Dans A. L., Munawar M.,O'Donnell M., Lawrence J., Lewis G., Afzal R., Yusuf S., Investigators A. S. C. a.Apixaban in patients with atrial fibrillation // N Engl J Med. ‒ 2011. ‒ T. 364, № 9. ‒ C.806-17.45. Coresh J., Astor B. C., Greene T., Eknoyan G., Levey A. S. Prevalence of chronickidney disease and decreased kidney function in the adult US population: Third NationalHealth and Nutrition Examination Survey // Am J Kidney Dis.
‒ 2003. ‒ T. 41, № 1. ‒ C.1-12.11546. Coresh J., Selvin E., Stevens L. A., Manzi J., Kusek J. W., Eggers P., Van Lente F.,Levey A. S. Prevalence of chronic kidney disease in the United States // JAMA. ‒ 2007.‒ T. 298, № 17. ‒ C. 2038-47.47. Cortese F., Scicchitano P., Gesualdo M., Ricci G., Carbonara S., Franchini C., PiaSchiavone B. I., Corbo F., Ciccone M. M. Apixaban: Effective and Safe in PreventingThromboembolic Events in Patients with Atrial Fibrillation and Renal Failure // Curr MedChem.
‒ 2017. ‒ T. 24, № 34. ‒ C. 3813-3827.48. Coumadin® (warfarin) prescribing information. BristolMyers Squibb Co., Princeton,NJ; https://packageinserts.bms.com/pi/pi_coumadin.pdf. ‒ 2018 (Дата обращения:12.06.2018.49. Dahal K., Kunwar S., Rijal J., Schulman P., Lee J. Stroke, Major Bleeding, andMortality Outcomes in Warfarin Users With Atrial Fibrillation and Chronic KidneyDisease: A Meta-Analysis of Observational Studies // Chest. ‒ 2016. ‒ T. 149, № 4. ‒ C.951-9.50. De Caterina R., Lip G. Y. H.
The non-vitamin K antagonist oral anticoagulants(NOACs) and extremes of body weight-a systematic literature review // Clin Res Cardiol.‒ 2017. ‒ T. 106, № 8. ‒ C. 565-572.51. De Vriese A. S., Caluwé R., Bailleul E., De Bacquer D., Borrey D., Van Vlem B.,Vandecasteele S. J., Emmerechts J.
Dose-finding study of rivaroxaban in hemodialysispatients // Am J Kidney Dis. ‒ 2015. ‒ T. 66, № 1. ‒ C. 91-8.52. Deo R., Katz R., Kestenbaum B., Fried L., Sarnak M. J., Psaty B. M., Siscovick D.S., Shlipak M. G. Impaired kidney function and atrial fibrillation in elderly subjects // JCard Fail. ‒ 2010. ‒ T. 16, № 1. ‒ C. 55-60.53. Dias C., Moore K. T., Murphy J., Ariyawansa J., Smith W., Mills R.
M., Weir M. R.Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Rivaroxaban inChronic Hemodialysis // Am J Nephrol. ‒ 2016. ‒ T. 43, № 4. ‒ C. 229-36.54. DiMarco J. P., Flaker G., Waldo A. L., Corley S. D., Greene H. L., Safford R. E.,Rosenfeld L. E., Mitrani G., Nemeth M., Investigators A. Factors affecting bleeding risk116during anticoagulant therapy in patients with atrial fibrillation: observations from theAtrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study //Am Heart J. ‒ 2005.
‒ T. 149, № 4. ‒ C. 650-6.55. Eckardt K. U., Coresh J., Devuyst O., Johnson R. J., Köttgen A., Levey A. S., LevinA. Evolving importance of kidney disease: from subspecialty to global health burden //Lancet. ‒ 2013. ‒ T. 382, № 9887. ‒ C. 158-69.56. Eikelboom JW, Connolly SJ, Gao P, Paolasso E, De Caterina R, Husted S, O'DonnellM, Yusuf S, Hart RG. Stroke risk and efficacy of apixaban in atrial fibrillation patientswith moderate chronic kidney disease // J Stroke Cerebrovasc Dis. ‒ 2012. ‒ T. 21.
‒ C.429 - 435.57. Eriksson B. I., Quinlan D. J., Eikelboom J. W. Novel oral factor Xa and thrombininhibitors in the management of thromboembolism // Annu Rev Med. ‒ 2011. ‒ T. 62. ‒C. 41-57.58. Fang M. C., Go A. S., Chang Y., Borowsky L. H., Pomernacki N. K., Udaltsova N.,Singer D. E. Warfarin discontinuation after starting warfarin for atrial fibrillation // CircCardiovasc Qual Outcomes. ‒ 2010. ‒ T.
3, № 6. ‒ C. 624-31.59. Fanola C. L., Mooney D., Cowan A. J., Ko D., Sisson E. K., Henault L. E., TripodisY., Hylek E. M. Incidence of severe renal dysfunction among individuals taking warfarinand implications for non-vitamin K oral anticoagulants // Am Heart J. ‒ 2017. ‒ T. 184.‒ C. 150-155.60. Foley R. N. Clinical epidemiology of cardiac disease in dialysis patients: leftventricular hypertrophy, ischemic heart disease, and cardiac failure // Semin Dial. ‒ 2003.‒ T. 16, № 2.
‒ C. 111-7.61. Fordyce C. B., Hellkamp A. S., Lokhnygina Y., Lindner S. M., Piccini J. P., BeckerR. C., Berkowitz S. D., Breithardt G., Fox K. A., Mahaffey K. W., Nessel C. C., SingerD. E., Patel M. R., Investigators R. A. S. C. a. On-Treatment Outcomes in Patients WithWorsening Renal Function With Rivaroxaban Compared With Warfarin: Insights FromROCKET AF // Circulation.
‒ 2016. ‒ T. 134, № 1. ‒ C. 37-47.11762. Foundation N. K. K/DOQI clinical practice guidelines for chronic kidney disease:evaluation, classification, and stratification // Am J Kidney Dis. ‒ 2002. ‒ T. 39, № 2Suppl 1. ‒ C. S1-266.63. Fox K. A., Piccini J. P., Wojdyla D., Becker R. C., Halperin J. L., Nessel C. C., PaoliniJ. F., Hankey G. J., Mahaffey K.
W., Patel M. R., Singer D. E., Califf R. M. Preventionof stroke and systemic embolism with rivaroxaban compared with warfarin in patientswith non-valvular atrial fibrillation and moderate renal impairment // Eur Heart J. ‒ 2011.‒ T. 32, № 19. ‒ C. 2387-94.64. Freedman B., Potpara T. S., Lip G. Y. Stroke prevention in atrial fibrillation // Lancet.‒ 2016. ‒ T. 388, № 10046. ‒ C. 806-17.65.
Freedman B., Camm J., Calkins H., Healey J. S., Rosenqvist M., Wang J., Albert C.M., Anderson C. S., Antoniou S., Benjamin E. J., Boriani G., Brachmann J., Brandes A.,Chao T. F., Conen D., Engdahl J., Fauchier L., Fitzmaurice D. A., Friberg L., Gersh B.J., Gladstone D. J., Glotzer T. V., Gwynne K., Hankey G. J., Harbison J., Hillis G.
S.,Hills M. T., Kamel H., Kirchhof P., Kowey P. R., Krieger D., Lee V. W. Y., Levin L.,Lip G. Y. H., Lobban T., Lowres N., Mairesse G. H., Martinez C., Neubeck L., OrchardJ., Piccini J. P., Poppe K., Potpara T. S., Puererfellner H., Rienstra M., Sandhu R. K.,Schnabel R. B., Siu C.
W., Steinhubl S., Svendsen J. H., Svennberg E., ThemistoclakisS., Tieleman R. G., Turakhia M. P., Tveit A., Uittenbogaart S. B., Van Gelder I. C.,Verma A., Wachter R., Yan B. P., Collaborators A.-S. Screening for Atrial Fibrillation:A Report of the AF-SCREEN International Collaboration // Circulation. ‒ 2017. ‒ T. 135,№ 19.
‒ C. 1851-1867.66. Friberg L., Benson L., Lip G. Y. Balancing stroke and bleeding risks in patients withatrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study // EurHeart J. ‒ 2015. ‒ T. 36, № 5. ‒ C. 297-306.67. Fuster V., Rydén L. E., Cannom D. S., Crijns H. J., Curtis A. B., Ellenbogen K. A.,Halperin J. L., Le Heuzey J. Y., Kay G. N., Lowe J. E., Olsson S.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
